2013 News Releases

Webcast ImageWebcast
Zogenix, Inc. at Oppenheimer 27th Annual Healthcare Conference (Replay)
03/22/17 at 2:10 p.m. ET
Zogenix, Inc. at Oppenheimer 27th Annual Healthcare Conference
Wednesday, March 22, 2017 2:10 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/20/13Zogenix Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued an inducement award to Bradley S. Galer, M.D., the company's newly appointed Executive Vice President and Chief Medical Officer. The award was made on December 17, 2013 under Zogenix's Employment Inducement Equity Incentive Award Plan, which provides for the ... 
Printer Friendly Version
12/17/13Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team
Additional Clinical and Medical Affairs Leaders Join Zogenix to Support Zohydro(TM) ER Launch SAN DIEGO, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today the expansion of its senior leadership team in support of the planned launch of Zohydro™ ER (hydrocodone bitartrate) extended-release capsules in March 2014. This includes the appointmen... 
Printer Friendly Version
12/11/13Zogenix Reports Granting of Inducement Awards
SAN DIEGO, Dec. 11, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued inducement awards to twelve new non-executive employees. The awards were made on December 9, 2013 under Zogenix's Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix. The inducement a... 
Printer Friendly Version
12/10/13Zogenix Announces FDA Approval of 4 mg SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-Free Delivery System
SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders and pain, announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for a 4 mg dose of SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System. SUMAVEL DosePro has been available in a 6 mg dose for the treatment of acute mig... 
Printer Friendly Version
12/04/13Zogenix to Present at the Oppenheimer 24th Annual Healthcare Conference
SAN DIEGO, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that Ann Rhoads, Chief Financial Officer will present at the Oppenheimer 24th Annual Healthcare Conference in New York on December 11, 2013. Event: Oppenheimer 24th Annual Healthcare Conference Date: Wednesday, December 11, 2013 Place: New York City ... 
Printer Friendly Version
12/03/13Zogenix and Battelle Expand DosePro Technology Business Agreement
New Long-Term Agreement Reflects Significant Opportunities to Out-License DosePro Technology SAN DIEGO and COLUMBUS, Ohio, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle today announced that they have entered into a new long-term collaborative agreement regarding co-marketing of Zogenix's DosePro® needle-free drug delivery technology, advancing potential out-licensing opportunities for DosePro with biopharmaceutical clients, and expanding the application of the techno... 
Printer Friendly Version
11/12/13Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
SAN DIEGO, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today the closing of its previously announced public offering of 30,666,667 shares of its common stock, including 4,000,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters, at a price to the public of $2.25 per share. The aggr... 
Printer Friendly Version
11/05/13Zogenix Prices Public Offering of Common Stock
SAN DIEGO, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today that it has priced an underwritten public offering of 26,666,667 shares of its common stock at a price to the public of $2.25 per share. Net proceeds, after underwriting discounts and commissions and estimated offering costs, are expected to be approximately $56 million. Zogeni... 
Printer Friendly Version
11/04/13Zogenix Announces Proposed Public Offering of Common Stock
SAN DIEGO, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today that it intends to offer and sell $60 million of shares of its common stock in an underwritten public offering. Zogenix also expects to grant to the underwriters for the offering a 30-day option to purchase additional shares of common stock, representing 15% of the offering amount,... 
Printer Friendly Version
11/04/13Zogenix Reports Third Quarter 2013 Financial Results
Business Highlights and Milestones Received FDA Approval for Zohydro™ ER (hydrocodone bitartrate), an extended-release oral formulation of hydrocodone without acetaminophen Announced development and option agreement with Altus Formulation Inc. for abuse deterrent formulations of Zohydro ER Began co-promotion of Migranal® (dihydroergotamine mesylate, USP) Nasal Spray in August SUMAVEL® DosePro® (sumatriptan injection) Third Quarter 2013 Highlights Net product re... 
Printer Friendly Version
11/01/13Zogenix Pursues Development of Abuse Deterrent Formulations of Zohydro(TM) ER With Altus Formulation
SAN DIEGO, Nov. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that it has entered into a Development and Option Agreement ("D&O Agreement") with Altus Formulation Inc. ("Altus"), a private Montreal-based drug formulation and development company, to develop abuse deterrent formulations of Zohydro™ ER (hydrocodone bitartrate) extended-relea... 
Printer Friendly Version
10/25/13Zogenix Receives FDA Approval for Zohydro(TM) ER (hydrocodone bitartrate) Extended-Release Capsules
Conference Call and Webcast on Monday, October 28, at 8:30 a.m. ET SAN DIEGO, Oct. 25, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that the U.S. Food and Drug Administration (FDA) has approved ZohydroTM ER (hydrocodone bitartrate) extended-release capsules, an opioid agonist, extended-release oral formulation of hydrocodone without acetaminop... 
Printer Friendly Version
10/01/13Zogenix Provides Update on Zohydro(TM) ER NDA
SAN DIEGO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced that it has been informed today by the U.S. Food and Drug Administration (FDA) that an action letter on the New Drug Application (NDA) for ZohydroTM ER (hydrocodone bitartrate) extended-release capsules could follow after a further delay of short duration. The FDA had previously informed... 
Printer Friendly Version
08/08/13Zogenix Reports Second Quarter 2013 Financial Results
Conference Call and Webcast Today, August 8, at 4:30 p.m. ET SUMAVEL® DosePro® (sumatriptan injection) Second Quarter 2013 Highlights Net product revenue of $8.9 million, up 11% over the second quarter 2012 Generated approximately 20,000 total prescriptions Maintained positive quarterly refill rate at 43%* Recent Highlights and Milestones Zohydro™ ER New Drug Application (NDA) still under review with FDA Entered exclusive U.S. co-promotion agreement f... 
Printer Friendly Version
08/05/13Zogenix Announces Conference Call and Webcast to Present Second Quarter 2013 Financial Results
Conference Call Scheduled for August 8, 2013 at 4:30 pm ET SAN DIEGO, Aug. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the second quarter ended June 30, 2013, after the market closes on Thursday, August 8, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss thes... 
Printer Friendly Version
08/01/13Zogenix Begins Promotion of Migranal(R) Nasal Spray
Expands Portfolio of Differentiated Migraine Therapies SAN DIEGO, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that its sales force has initiated promotion of Migranal® (dihydroergotamine mesylate, USP) Nasal Spray in the United States under the company's exclusive co-promotion agreement with Valeant Pharmaceuticals North America LLC. ... 
Printer Friendly Version
06/27/13Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Migranal(R) Nasal Spray
Zogenix Sales Force to Begin Promoting Migranal(R) to Its Customer Base of Neurologists and Headache Specialists SAN DIEGO, June 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today an exclusive co-promotion agreement for Migranal® (dihydroergotamine mesylate, USP) Nasal Spray in the United States. Under the terms of the agreement, Zogenix's s... 
Printer Friendly Version
06/25/13Zogenix Launches Improved Migraine Toolbox in Conjunction With National Migraine Awareness Month
Supports Patient Education and Empowerment for Managing Multiple Types of Migraine Attacks SAN DIEGO, June 25, 2013 (GLOBE NEWSWIRE) -- In conjunction with National Migraine Awareness Month and in recognition of the significant unmet needs of migraine sufferers, Zogenix, Inc. (Nasdaq:ZGNX) is launching a new and improved SUMAVEL® DosePro® Migraine Toolbox to support patient education and empowerment. The Migraine Toolbox highlights the importance of having the appropriate medication on hand in ... 
Printer Friendly Version
06/05/13Zogenix Announces Initiatives to Reach Key Business Milestones
Cost Control Initiatives Extend Cash Runway SAN DIEGO, June 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today initiatives to extend its cash runway to reach key business milestones that may occur over the remainder of the year. These milestones include the Company's efforts to gain U.S. Food and Drug Administration (FDA) approval for its New Dru... 
Printer Friendly Version
05/20/13Zogenix and Battelle to Present Positive, New Data Demonstrating Value of Needle-Free Injection for Biologics
DosePro Studies to be Presented at 2013 AAPS National Biotechnology Conference SAN DIEGO and COLUMBUS, Ohio, May 20, 2013 (GLOBE NEWSWIRE via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle Memorial Institute today announced new data supporting the value of the DosePro® needle-free injection technology in the delivery of biologics. The positive, new data will be presented in four poster presentations, including two posters co-authored by MedImmune, LLC, the worldwide biologics research... 
Printer Friendly Version
05/09/13Zogenix Reports First Quarter 2013 Financial Results
Provides Update on Zohydro ER Conference Call and Webcast Today, May 9, at 4:30 p.m. ET SUMAVEL® DosePro® (sumatriptan injection) First Quarter 2013 Highlights Net product revenue of $7.0 million, reflecting a $1.2 million net adjustment to future product return reserve Generated approximately 20,000 total prescriptions Maintained positive quarterly refill rate at 41%* Recent Highlights and Milestones Reported positive top-line results from extend... 
Printer Friendly Version
05/03/13Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these finan... 
Printer Friendly Version
05/02/13Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial
Initiates Efforts to Secure Strategic Development and Commercialization Partner SAN DIEGO, May 2, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced positive top-line results from its extended Phase 1 clinical trial of Relday™, an investigational candidate of a proprietary, once-monthly subcutaneous formulation of risperidone for the treatment of sc... 
Printer Friendly Version
03/27/13Zogenix and Battelle Extend DosePro Co-Marketing Partnership
SAN DIEGO and COLUMBUS, Ohio, Mar 27, 2013 (GLOBE NEWSWIRE via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Battelle, the world's largest independent research and development organization, today announced they have extended their co-marketing partnership for the DosePro® needle-free drug delivery system through March 29, 2014. The partnership is focused on advancing ... 
Printer Friendly Version
03/15/13Zogenix Reports Fourth Quarter and Full Year 2012 Financial Results
Conference Call and Webcast Today, March 15, at 8:30 a.m. ET SUMAVEL® DosePro® (sumatriptan injection) Highlights 2012 net product revenue of $35.9 million, up 18% over 2011 Fourth quarter net product revenue of $9.5 million, up 12% over third quarter Increased total prescriptions to over 83,000 in 2012, up 16% over 2011* Transitioned co-promotion responsibilities to Mallinckrodt's (Covidien) sales force, which began focused co-promotion at the beginning of October... 
Printer Friendly Version
03/07/13Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2012 Financial Results
Conference Call Scheduled for March 15, 2013 at 8:30 am ET SAN DIEGO, March 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the fourth quarter and full year ended December 31, 2012, before the market opens on Friday, March 15, 2013, and will hold a conference call on this day at 8:30 a.m. ET (5:30 a.m. PT)... 
Printer Friendly Version
02/26/13Zogenix Provides Update on Zohydro(TM) ER Regulatory Review
SAN DIEGO, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has been informed by the U.S. Food and Drug Administration (FDA) that Zogenix is unlikely to receive an action letter for its New Drug Application (NDA) for ZohydroTM ER (hydrocodone bitartrate extended-release capsules) by the Prescription Drug User Fee Act (PDUFA) goal d... 
Printer Friendly Version
01/07/13Zogenix Announces Preliminary Fourth Quarter 2012 Gross Product Sales
SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today preliminary unaudited gross product sales for the quarter ended December 31, 2012. Zogenix expects to report fourth quarter 2012 gross product sales of approximately $13.5 million on 145,200 units shipped, with unit volume up approximately 9% sequentially from third quarter 2012 an... 
Printer Friendly Version
01/03/13Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial
Plans to Seek Partner and Accelerate Development of Once-Monthly Subcutaneous Formulation of Risperidone for Schizophrenia SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced positive single-dose pharmacokinetic (PK) results from the Phase 1 clinical trial of Relday™, an investigational candidate of a proprietary, once-monthly subcu... 
Printer Friendly Version